Chardan Capital Reaffirms Buy Rating for uniQure (NASDAQ:QURE)

Chardan Capital reaffirmed their buy rating on shares of uniQure (NASDAQ:QURE - Free Report) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $38.00 price target on the biotechnology company's stock.

QURE has been the topic of a number of other reports. Guggenheim reiterated a "buy" rating and set a $28.00 target price on shares of uniQure in a research report on Monday, May 12th. HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of uniQure in a research report on Thursday. Wells Fargo & Company lowered their price objective on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a research note on Friday, February 28th. Wall Street Zen upgraded shares of uniQure from a "sell" rating to a "hold" rating in a research report on Saturday, May 24th. Finally, Cantor Fitzgerald raised shares of uniQure to a "strong-buy" rating in a report on Monday, May 19th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, uniQure has a consensus rating of "Moderate Buy" and an average target price of $37.82.

uniQure Price Performance

Shares of QURE traded down $0.34 during trading hours on Friday, reaching $14.56. The company had a trading volume of 1,712,177 shares, compared to its average volume of 1,908,946. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18. The firm has a 50 day simple moving average of $12.53 and a 200-day simple moving average of $12.91. The company has a market capitalization of $797.54 million, a price-to-earnings ratio of -2.94 and a beta of 0.10.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.07) by $0.25. The company had revenue of $1.57 million during the quarter, compared to the consensus estimate of $5.93 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. Research analysts expect that uniQure will post -3.75 earnings per share for the current year.

Insider Activity

In other uniQure news, CEO Matthew C. Kapusta sold 28,341 shares of uniQure stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the sale, the chief executive officer now owns 651,454 shares in the company, valued at $6,703,461.66. The trade was a 4.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Christian Klemt sold 10,438 shares of the company's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $107,407.02. Following the transaction, the chief financial officer now directly owns 217,730 shares of the company's stock, valued at approximately $2,240,441.70. This represents a 4.57% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,129 shares of company stock valued at $412,927 over the last 90 days. Insiders own 4.74% of the company's stock.

Institutional Investors Weigh In On uniQure

Hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. increased its position in uniQure by 9.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock worth $195,000 after purchasing an additional 969 shares during the last quarter. Tudor Investment Corp ET AL grew its stake in shares of uniQure by 5.9% during the 4th quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company's stock valued at $438,000 after buying an additional 1,371 shares during the period. Wells Fargo & Company MN increased its holdings in shares of uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock worth $217,000 after buying an additional 1,503 shares during the last quarter. Northern Trust Corp increased its holdings in shares of uniQure by 2.1% during the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock worth $1,688,000 after buying an additional 1,923 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of uniQure by 6.0% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company's stock worth $1,253,000 after buying an additional 3,996 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.